Publication | Closed Access

882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study

InflammationMedicineModerate-to-severe Ulcerative ColitisImmunologyGastroenterologyPathologyChronic InflammationUlcerative ColitisPhase 2Anti-interleukin-23 TherapyInflammatory DiseaseDigestive System Diseases